초록 ▼

A method of insuring the accuracy of transmitted or stored digital data involves the use of a cyclical redundancy check (CRC) code. The method is particularly useful for ensuring the accuracy of frames transmitted between multi-mode vocoders. The method allows a different CRC code to be used for eac

A method of insuring the accuracy of transmitted or stored digital data involves the use of a cyclical redundancy check (CRC) code. The method is particularly useful for ensuring the accuracy of frames transmitted between multi-mode vocoders. The method allows a different CRC code to be used for each mode of a transmitting multi-mode vocoder. A receiving multi-mode vocoder checks the CRC code against the CRC coding formulas of the various modes. If the CRC code is satisfied under any one of the modes, the frame is labeled as "good". If the CRC code fails under all the modes, the frame is labeled as "bad". If the bit frame includes bits for indicating the mode of the transmitting multi-mode vocoder, the receiving multi-mode vocoder checks the CRC code against the CRC coding formula for the indicated mode only. If the CRC code passes for the indicated mode, the frame is labeled as "good", otherwise, the frame is labeled as "bad".

대표청구항 ▼

A method of insuring the accuracy of transmitted or stored digital data involves the use of a cyclical redundancy check (CRC) code. The method is particularly useful for ensuring the accuracy of frames transmitted between multi-mode vocoders. The method allows a different CRC code to be used for eac

A method of insuring the accuracy of transmitted or stored digital data involves the use of a cyclical redundancy check (CRC) code. The method is particularly useful for ensuring the accuracy of frames transmitted between multi-mode vocoders. The method allows a different CRC code to be used for each mode of a transmitting multi-mode vocoder. A receiving multi-mode vocoder checks the CRC code against the CRC coding formulas of the various modes. If the CRC code is satisfied under any one of the modes, the frame is labeled as "good". If the CRC code fails under all the modes, the frame is labeled as "bad". If the bit frame includes bits for indicating the mode of the transmitting multi-mode vocoder, the receiving multi-mode vocoder checks the CRC code against the CRC coding formula for the indicated mode only. If the CRC code passes for the indicated mode, the frame is labeled as "good", otherwise, the frame is labeled as "bad". 990300, Herzig et al., 514/625; US-5914349, 19990600, Cohen et al., 514/657; US-5962458, 19991000, Lohmann et al., 544/287; US-5994408, 19991100, Cohen et al., 514/657; US-6103899, 20000800, Horne et al., 540/521; US-20020028782, 20020300, Castlehano et al.; US-20020094974, 20020700, Castlehano et al.; US-20030036545, 20030200, Castlehano et al.; US-20030045536, 20030300, Castlehano et al.; US-20030073708, 20030400, Castlehano et al. onscious sedation in a patient in need thereof comprising administering to the patient a composition comprising a compound having the formula: or pharmaceutically acceptable salts thereof wherein: n is 0 or 1; Z is an O or S; and R1,R2,and R3are independently selected from the group consisting of H, an optionally substituted alkyl or alkenyl group, and an optionally substituted phenylmethyl group, with the exceptions that: R1and R2cannot both be H; when one of R1or R2is H or a methyl group, the other of R1or R2cannot be a methyl or ethyl group; and when n=1, R1and R2cannot both be ethyl. 2. The method of claim 1, wherein said compound has a water solubility of between 0.1 g per 1.0 g of water and the point of saturation. 3. The method of claim 2, wherein said compound has a water solubility of between 0.5 g per 1.0 g of water and the point of saturation. 4. The method of claim 3, wherein said compound has a water solubility of between 1.0 g per 1.0 g of water and the point of saturation. 5. The method of claim 1, wherein said composition comprises water or buffer. 6. The method of claim 1, wherein said compound is administered intravenously. 7. The method of claim 1, wherein said compound is administered orally. 8. The method of claim 1, wherein said compound is administered rectally, intramuscularly, subcutaneously, or through an inhalation administration. 9. The method of claim 1, wherein said compound is given at a dosage of from 1-1000 mg/kg. 10. The method of claim 9, wherein said compound is given at a dosage of from 100-1000 mg/kg. 11. The method of claim 9, wherein said compound is given at a dosage of from 10-100 mg/kg. 12. The method of claim 1, wherein said compound is in an enantiomerically enriched mixture. 13. The method of claim 1, wherein said compound is 3,3-diethyl-2-pyrrolidinone. 14. The method of claim 1, wherein said compound produces an onset of anesthesia in less than 5 minutes after administration. 15. The method of claim 14, wherein said compound produces an onset of anesthesia in less than 1 minute after administration. 16. The method of claim 15, wherein said compound produces an onset of anesthesia in less than 10 seconds after administration.